Medical technology company Bibb Instruments reports increased net sales and a larger loss in the first quarter of 2026 compared with the corresponding period the previous year. Net sales amounted to SEK 0.1 million (0), while operating profit deteriorated to SEK -4.8 million (-2.9). Earnings per share amounted to SEK -0.12 (-0.08). The company states that the weaker earnings trend is mainly explained by previously capitalized development expenses now being recognized directly as costs since sales of the products have begun. "After the rights issue completed in April, Bibbinstruments continues the commercial expansion of Endodrill GI in the US together with distribution partner TaeWoong Medical USA. At the same time, work continues to establish a distribution partnership in Europe and prepare the next product variant in the platform, Endodrill EBUS for lung cancer," writes CEO Fredrik Lindblad. Bibb Instruments, SEK millionQ1 2026Q1 2025ChangeRevenue0.10192%Operating profit-4.8-2.9-68%Profit before tax-4.8-2.9-66%Earnings per share, SEK-0.12-0.08-50%